Contents
Academic literature on the topic 'Plaque-type psoriasis, Psoriasis Area and Severity Index, Dermatology Life Quality Index'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Plaque-type psoriasis, Psoriasis Area and Severity Index, Dermatology Life Quality Index.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Plaque-type psoriasis, Psoriasis Area and Severity Index, Dermatology Life Quality Index"
1
Roongpisuthipong, Wanjarus, Marinya Pongpudpunth, Chulaporn Roongpisuthipong, and Natta Rajatanavin. "The Effect of Weight Loss in Obese Patients with Chronic Stable Plaque-Type Psoriasis." Dermatology Research and Practice 2013 (2013): 1–5. http://dx.doi.org/10.1155/2013/795932.
Full textAbstract:
Background. Chronic plaque psoriasis is frequently associated with obesity. The effect of a low-calorie diet on psoriasis has not been investigated.Objective. The objective was to investigate whether moderate weight loss increases the therapeutic response to topical treatment in obese patients with chronic stable plaque-type psoriasis.Material and Method. A 24-week clinical trial was conducted in 10 patients. The efficacy of a low-calorie diet with topical treatment was compared with baseline in obese patients with chronic stable plaque-type psoriasis. The primary measure of clinical response was the Psoriasis Area and Severity Index at weeks 12 and 24.Results. At week 12, the mean reduction in body weight was 9.6 percent. There was an improvement from baseline of 50 percent or more in the Psoriasis Area and Severity Index in 50 percent of the patients. The responses as measured by improvements in the Psoriasis Area and Severity Index were paralleled by improvements in global assessments by the physician and the patients and in the Dermatology Life Quality Index.Conclusion. Obese patients with chronic stable plaque-type psoriasis increase their response to a low-calorie diet. Lifestyle modifications, including a low-calorie diet, may supplement the pharmacologic treatment of obese psoriasis patients.
2
Michalak-Stoma, Anna, Joanna Bartosińska, Małgorzata Kowal, Dorota Raczkiewicz, Dorota Krasowska, and Grażyna Chodorowska. "IL-17A in the Psoriatic Patients’ Serum and Plaque Scales as Potential Marker of the Diseases Severity and Obesity." Mediators of Inflammation 2020 (June 5, 2020): 1–9. http://dx.doi.org/10.1155/2020/7420823.
Full textAbstract:
The aim of the study was to evaluate concentrations of IL-17 in the serum and plaque scales of psoriatic patients. We analyzed their association with the clinical activity of the disease and with body mass index (BMI). Demographic data, medical history, serum, and scale from psoriatic plaques for assessment of IL-17 were collected from all the participants. The disease severity was assessed with PASI (Psoriasis Area and Severity Index), BSA (Body Surface Area), PGA (Physician Global Assessment), NAPSI (Nail Psoriasis Severity Index), and DLQI (Dermatology Quality of Life Index) scores. Obesity was diagnosed by calculating body mass index. Serum and scale concentration of IL-17 was determined with Human IL-17A High Sensitivity ELISA kit and Human IL-17 ELISA kit. In the psoriatic patients, BMI was statistically significantly higher than in the control group. Most of the patients presented BMI higher than normal. Our study confirms that overweight is a problem among psoriatic patients. A significant positive correlation between the IL-17 serum and scale concentrations and psoriasis severity indicates that IL-17 can be used as the marker of disease severity. More data from human studies can be crucial for understanding that relationship between IL-17, psoriasis, and obesity.
3
Poulin, Yves, Aditya K. Gupta, and John D. Amiss. "Efficacy of Etanercept in the Management of Plaque Psoriasis and Psoriatic Arthritis." Journal of Cutaneous Medicine and Surgery 11, no. 2_suppl (March 2007): S14—S22. http://dx.doi.org/10.2310/7750.2006.00070.
Full textAbstract:
Etanercept is a fully human dimeric fusion protein that reversibly binds tumor necrosis factor α. The first approved indication for etanercept was for the treatment of rheumatoid arthritis. It has also been shown to be highly efficacious in numerous large-scale trials for the treatment of plaque psoriasis; this indication was approved in Canada, the United States, and Europe. The recommended dosing of etanercept for plaque psoriasis is 50 mg twice weekly for 12 weeks, followed by a maintenance dose of 50 mg per week. Etanercept given at 50 mg twice weekly for 12 weeks significantly improved plaque psoriasis, as assessed by the Psoriasis Area and Severity Index (PASI), in which 75% reduction in PASI scores (PASI 75) has been the gold standard for judging effective therapy. Dosing given for 12 weeks produced PASI 75 rates of 47 to 49% in the phase 3 clinical trials. Longer treatment periods at this dosage have been investigated, from 24 to 48 weeks, with PASI 75 increasing to 63%. The importance of quality of life for psoriasis patients has been the focus of recent trials, and etanercept has been shown significant improvement in quality of life measures. Interim results from a phase 3b study suggest that etanercept may help reduce the burden of health care resources use by psoriatics. Etanercept has also shown efficacy in nail psoriasis. Case reports indicate that etanercept may be useful in psoriatic erythroderma, pustular psoriasis, guttate psoriasis, and palmopustular psoriasis. Etanercept is an effective biologic agent currently approved for the management of plaque psoriasis and psoriatic arthritis.
4
Sekar, Suganya, and Samuel J. Daniel. "A clinico-epidemiological study of psoriasis patients with moderate to severe plaque type in tertiary care centre in South India." International Journal of Research in Dermatology 7, no. 1 (December 24, 2020): 1. http://dx.doi.org/10.18203/issn.2455-4529.intjresdermatol20204934.
Full textAbstract:
<p class="abstract"><strong>Background:</strong> Psoriasis is a chronic disorder with the most common manifestation being the plaque-type. Nearly 20% of the plaque type suffer from a disease of moderate to severe intensity with immense effect on the quality of life. Aim was to study the clinical, socio-economic and demographic characteristics of patients with moderate to severe plaque type of psoriasis.</p><p class="abstract"><strong>Methods:</strong> This was an observational study conducted in about fourty patients diagnosed with moderate to severe plaque type of psoriasis based upon the clinical history, morphology of the lesions and assessed using psoriasis area and severity index (PASI), dermatology life quality index (DLQI) scoring and for comorbidities. Data was compiled and analyzed with statistical package for social science (SPSS) Version 20.0.</p><p class="abstract"><strong>Results:</strong> Mean age was 37.43±10.1 years. 22 were males (55%) and 18 were females (45%). The mean duration was 8.93 years and 15% had family history. The mean age of onset was earlier in the females (20.23 years) with a positive family history, as compared to males (25.36 years). About 62.5% had moderate psoriasis and 37.5% had severe psoriasis. At the baseline the PASI score was 31.98±6.08 and DLQI score was 36. About 67.5% had nail changes and 10% had psoriatic arthritis. Almost in half (47.5%) the duration of the disease was 1 to 5 years and scalp (32.5%) the most common initial site of involvement. Various comorbidities were documented, 72% in moderate psoriasis and 73.33% in severe psoriasis with dyslipidemia (67.5%) being commonest.</p><p class="abstract"><strong>Conclusions:</strong> Patients with moderate to severe psoriasis mostly have a low quality of life with multiple significant co-morbidities that increases the risk for morbidity and mortality. </p>
5
Park, So Young, and Kon Hee Kim. "What Factors Influence on Dermatology-Related Life Quality of Psoriasis Patients in South Korea?" International Journal of Environmental Research and Public Health 18, no. 7 (March 31, 2021): 3624. http://dx.doi.org/10.3390/ijerph18073624.
Full textAbstract:
This descriptive study aimed to identify factors that can influence the quality of life of psoriasis patients. A total of 118 psoriasis outpatients completed a questionnaire consisting of the Dermatology Life Quality Index (DLQI), Psoriasis Life Stress Inventory (PLSI), Mishel Uncertainty in Illness Scale-Community form (MUIS-C), Center for Epidemiologic Studies-Depression scale (CES-D), and Self-Reported Severity Score (SRSS). The Psoriasis Area Severity Index (PASI) was calculated. The collected data were analyzed by descriptive statistics, t-test, one-way ANOVA, Scheffé test, Pearson’s correlation analysis, and stepwise multiple regression using SPSS/WIN 26.0. The average score of the DLQI was 14.19 ± 6.83 (range 0–30); the DLQI showed statistically significant differences according to age (F = 4.02, p = 0.021) and smoking type (F = 7.49, p = 0.001). The dermatology-related quality of life was significantly affected by psoriasis-related stress (β = 0.37, p < 0.001), depression (β = 0.35, p < 0.001), and subjective severity (β = 0.19, p = 0.005); these variables explained 60.7% of the variance in the dermatology-related quality of life (F = 61.34, p < 0.001). The results demonstrated that psoriasis-related stress, depression, and perceived severity of psoriasis should be considered when developing nursing interventions to improve patients’ quality of life.
6
Amy de la Breteque, M., A. Beauchet, N. Quiles-Tsimaratos, E. Estève, T. Le Guyadec, M. Ruer-Mulard, F. Maccari, et al. "Characteristics of patients with plaque psoriasis who have discordance between Psoriasis Area Severity Index and dermatology life quality index scores." Journal of the European Academy of Dermatology and Venereology 31, no. 5 (November 14, 2016): e269-e272. http://dx.doi.org/10.1111/jdv.14021.
Full text
7
Cassano, N., F. Loconsole, A. Galluccio, A. Miracapillo, M. Pezza, and G. A. Vena. "Once-Weekly Administration of High-Dosage Etanercept in Patients with Plaque Psoriasis: Results of a Pilot Experience (Power Study)." International Journal of Immunopathology and Pharmacology 19, no. 1 (January 2006): 205873920601900. http://dx.doi.org/10.1177/205873920601900123.
Full textAbstract:
Etanercept is a soluble tumour necrosis factor receptor fusion protein which is approved for the treatment of plaque psoriasis at the dose of either 25mg twice weekly (BIW) or, for the initial 12 weeks, 50mg BIW. Alternative dosing regimens have not been evaluated in psoriasis. In this study, we compare the efficacy and tolerability of two etanercept dosing regimens - 50mg BIW and 100mg once weekly (OW) - for 12 weeks in 108 patients with moderate-to-severe recalcitrant psoriasis. Efficacy measures included Psoriasis Area and Severity Index (PASI), severity of pruritus recorded on a visual analogue scale (VAS) and the influence on quality of life assessed by means of Dermatology Life Quality Index (DLQI). Both etanercept regimens caused a significant change in all the efficacy parameters after 4 weeks and 12 weeks, at a comparable rate. At week 12, a PASI improvement of at least 50% from baseline (PASI 50) was achieved by 74% of patients treated with 50mg BIW and 78% of patients treated with 100mg OW. A PASI 75 response was obtained in 54% and 50% of patients treated with 50mg BIW and 100mg OW, respectively. Treatment was well tolerated with similar type and frequency of adverse events between the two groups.
8
Stojkovic, Tatjana, Marina Hadzi-Pesic, Natasa Savic, and Ivan Stojkovic. "Evaluation of life quality in patients with psoriasis." Psihologija 48, no. 3 (2015): 267–77. http://dx.doi.org/10.2298/psi1503267s.
Full textAbstract:
Psoriasis is a disease that has a profound impact on all aspects of life quality because over years patients are faced not only with poor health, but also with a number of restrictions imposed by the disease in their professional, social and emotional life. The aim of the study was to assess the level of impairment to the life quality in patients with chronic plaque psoriasis in relation to the clinical status of the disease, disease duration, and age and gender of the examinees. The cross-sectional study was conducted at the Clinic for Skin and Venereal Diseases of the Clinical Center of Nis. The total sample consisted of 142 examinees, 82 in the primary group (patients with psoriasis), and 60 in the control group (healthy volunteers). In order to assess the impact of psoriasis on life quality and compare it to the life quality of healthy population, the DLQI questionnaire (Dermatology Life Quality Index)was used and the disease severity was estimated based on the value of the PASI score (Psoriasis Area and Severity Index). The results showed that the groups of examinees differ appreciably in self-assessment in all five dimensions of life quality. In patients with psoriasis, there was statistically significantly lower life quality as a reflection of the disease severity and subjective perceptions of the disease impact and treatment impact, but also as a result of a number of restrictions in daily functioning caused by the disease. Patients with a severer clinical status gave low ratings to their ability to function in all areas covered by the DLQI questionnaire, especially in the symptoms and feelings subscale. The results of our study indicate the importance of a multidisciplinary approach in the treatment of patients with psoriasis and the possibility of introducing a supportive therapy, which would, along with a regular dermatological therapy, notably improve the life quality of these patients.
9
G. V., Amruthavalli, Aruna V., and Gayathri R. "Clinical trial of combination therapy for the efficacy, safety, tolerability and improvements in quality of life in patients with moderate to severe plaque psoriasis." International Journal of Clinical Trials 5, no. 3 (July 24, 2018): 121. http://dx.doi.org/10.18203/2349-3259.ijct20183180.
Full textAbstract:
<p class="abstract"><strong>Background:</strong> Psoriasis is an autoimmune disorder with clinical manifestations scales, inflammation and dryness. The psoriatic skin behaves differently in concurrence with circadian rhythm. Cell division increases in late night and early morning hours. Enzymatic activity will be more during day time. To balance these variations a 24×7 protection is required. The objective of the present study is to find the improvement in Psoriasis condition with the Combination therapy compared to single drug usage.</p><p class="abstract"><strong>Methods:</strong> A clinical trial for 4 weeks was conducted among psoriasis patients with psorolin oil vs. combination therapy (Dr. JRK’s 777 oil, psorolin ointment, psorolin oil and psorolin medicated bathing bar) and the clinical relief was measured among both groups by following parameters like psoriasis area and severity index (PASI), Physician’s global assessment (PGA), dermatology life quality index (DLQI), subjective self-assessment questionnaire (SSAQ) and subject investigational product feedback questionnaire (SIPFBQ).</p><p class="abstract"><strong>Results:</strong> Combination therapy (1-3-2 topical therapy) of Dr. JRK’s 777 oil, psorolin ointment, psorolin oil and psorolin medicated bathing bar as a treatment regimen was found to be more effective in the treatment of psoriasis.</p><p class="abstract"><strong>Conclusions: </strong>1-3-2 topical therapy is useful in severe psoriasis conditions and recommended for long term effective treatment of psoriasis.</p><p class="abstract"> </p>
10
AlMutairi, Nawaf, and Tarek Nour. "Tofacitinib in Pediatric Psoriasis: An Open-Label Trial to Study Its Safety and Efficacy in Children." Dermatology 236, no. 3 (October 30, 2019): 191–98. http://dx.doi.org/10.1159/000503062.
Full textAbstract:
Introduction: Psoriasis is a chronic, multifactorial, inflammatory disorder, with an estimated prevalence of 0.71% in children. The commonly used therapeutic agents target the underlying inflammation. Tofacitinib has demonstrated efficacy in adult psoriasis. Aim: To study the efficacy, safety, and tolerability of tofacitinib in pediatric patients with moderate to severe chronic plaque psoriasis. Methods: The study included children aged between 8 and 17 years, with moderate to severe psoriasis, given tofacitinib 5 mg orally twice daily for at least 36 weeks. The clinical response was estimated using the Psoriasis Area and Severity Index (PASI) score, Physician’s Global Assessment (PGA), and the Children’s Dermatology Life Quality Index (CDLQI). The incidence and severity of adverse events (AEs) were meticulously recorded in each case. Results: A total of 47 patients, with a median age of 12.3 years, completed the study. At week 12, 55.32% achieved PASI 75, and 70.21% at week 36. PGA of clear or almost clear responses at week 12 were 59.57 and 65.96%, respectfully, at week 36. Relatively few and mostly minor adverse effects were noted. No severe AEs were reported. Conclusion: The treatment with tofacitinib was safe and well tolerated, and led to significant improvement of their disease and quality of life as reflected in CDLQI scores. However, the results need to be validated in larger multicenter trials.
Dissertations / Theses on the topic "Plaque-type psoriasis, Psoriasis Area and Severity Index, Dermatology Life Quality Index"
1
Schmitt, Jochen, and Gottfried Wozel. "The Psoriasis Area and Severity Index Is the Adequate Criterion to Define Severity in Chronic Plaque-Type Psoriasis." Saechsische Landesbibliothek- Staats- und Universitaetsbibliothek Dresden, 2014. http://nbn-resolving.de/urn:nbn:de:bsz:14-qucosa-135547.
Full textAbstract:
Background: Chronic plaque-type psoriasis is a major dermatosis, but a significant question is still unanswered: What defines severity in chronic plaque-type psoriasis? While objective assessments like the Psoriasis Area and Severity Index (PASI) have frequently been used in clinical trials, quality of life (QOL) questionnaires are currently becoming more and more popular. Objective: This article summarizes the most important objective and subjective measurements of severity in psoriasis. For every dermatologist it is critically important to distinguish between severe psoriasis and psoriasis that severely affects QOL. Even if the PASI also has disadvantages, it is the most adequate instrument available to evaluate severity in plaque-type psoriasis. Result: We provide reasons why PASI >12 defines severe, PASI 7–12 moderate and PASI <7 mild chronic plaque-type psoriasisDieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich
2
Schmitt, Jochen, and Gottfried Wozel. "The Psoriasis Area and Severity Index Is the Adequate Criterion to Define Severity in Chronic Plaque-Type Psoriasis." Karger, 2005. https://tud.qucosa.de/id/qucosa%3A27658.
Full textAbstract:
Background: Chronic plaque-type psoriasis is a major dermatosis, but a significant question is still unanswered: What defines severity in chronic plaque-type psoriasis? While objective assessments like the Psoriasis Area and Severity Index (PASI) have frequently been used in clinical trials, quality of life (QOL) questionnaires are currently becoming more and more popular. Objective: This article summarizes the most important objective and subjective measurements of severity in psoriasis. For every dermatologist it is critically important to distinguish between severe psoriasis and psoriasis that severely affects QOL. Even if the PASI also has disadvantages, it is the most adequate instrument available to evaluate severity in plaque-type psoriasis. Result: We provide reasons why PASI >12 defines severe, PASI 7–12 moderate and PASI <7 mild chronic plaque-type psoriasis.Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich.
3
Schmitt, Jochen, Elisabeth Heese, Gottfried Wozel, and Michael Meurer. "Effectiveness of Inpatient Treatment on Quality of Life and Clinical Disease Severity in Atopic Dermatitis and Psoriasis Vulgaris – A Prospective Study." Saechsische Landesbibliothek- Staats- und Universitaetsbibliothek Dresden, 2014. http://nbn-resolving.de/urn:nbn:de:bsz:14-qucosa-135494.
Full textAbstract:
Background: Financial constraints challenge evidence of the effectiveness of dermatological inpatient management. Objective: To evaluate the effectiveness of hospitalization in atopic dermatitis and psoriasis regarding initial and sustained benefits. Methods: Prospective study on adults with psoriasis vulgaris (n = 22) and atopic dermatitis (n = 14). At admission, discharge, and 3 months after discharge, validated outcomes of objective and subjective disease severity were assessed by trained investigators. Results: Hospitalization resulted in substantial benefit in quality of life and clinical disease severity. Looking at mean scores, the observed benefit appeared stable until 3-month follow-up. The analysis of individual patient data revealed significant changes in disease severity between discharge and 3-month follow-up with some patients relapsing, others further improving. Reasons for hospitalization and treatment performed were not related to sustained benefit. Conclusions: In psoriasis vulgaris and atopic dermatitis, hospitalization effectively improved quality of life and clinical disease severity. Further research should focus on prognostic factors for sustained improvementDieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich
4
Schmitt, Jochen, Elisabeth Heese, Gottfried Wozel, and Michael Meurer. "Effectiveness of Inpatient Treatment on Quality of Life and Clinical Disease Severity in Atopic Dermatitis and Psoriasis Vulgaris – A Prospective Study." Karger, 2007. https://tud.qucosa.de/id/qucosa%3A27655.
Full textAbstract:
Background: Financial constraints challenge evidence of the effectiveness of dermatological inpatient management. Objective: To evaluate the effectiveness of hospitalization in atopic dermatitis and psoriasis regarding initial and sustained benefits. Methods: Prospective study on adults with psoriasis vulgaris (n = 22) and atopic dermatitis (n = 14). At admission, discharge, and 3 months after discharge, validated outcomes of objective and subjective disease severity were assessed by trained investigators. Results: Hospitalization resulted in substantial benefit in quality of life and clinical disease severity. Looking at mean scores, the observed benefit appeared stable until 3-month follow-up. The analysis of individual patient data revealed significant changes in disease severity between discharge and 3-month follow-up with some patients relapsing, others further improving. Reasons for hospitalization and treatment performed were not related to sustained benefit. Conclusions: In psoriasis vulgaris and atopic dermatitis, hospitalization effectively improved quality of life and clinical disease severity. Further research should focus on prognostic factors for sustained improvement.Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich.